BMY250117P25000
- 0.01
- 0.000.00%
Bristol-Myers Squibb Newsroom
Bristol Sees Annual $1.5B in Cost Savings by End of 2025
Bristol-Myers Squibb Unveils Strategic Growth Plan
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
Bristol-Myers Squibb To Present At J.P. Morgan's Healthcare Conference; Webcast At 10:30 AM ET
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $70
Express News | Bristol-Myers Squibb Canada: Car T Cell Therapy Breyanzi Approved for Second-Line Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bristol-Myers Squibb Company Exercises Exclusive License Option for ArsenalBio's AB-4000 Series
Express News | Arsenalbio: Eligible for Additional Milestone Payments and Royalties as Programs Advance
Express News | Arsenalbio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
10 Levered Big-caps That May Face Higher Refinancing Expenses
Bernstein Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $62
Bernstein Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
Medicare Drug Prices Nearly Double, Surpassing Inflation: AARP
Bristol-Myers Squibb Hits 4-week Low
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $52 From $53, Maintains Neutral Rating
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock
Express News | Light Horse: Financing Led by Versant Ventures and Included Mubadala Capital, Bristol-Myers, Taiho Ventures, and Abbvie